Skip to main
PRVA

PRVA Stock Forecast & Price Target

PRVA Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 69%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Privia Health Group Inc. has demonstrated significant growth, achieving the addition of 125 providers in the fourth quarter of 2025, with strong expectations for ongoing performance due to favorable trends in the Arizona market. The company reported a sequential increase of approximately 9% in practice collections per provider, translating to about $80 million, driven by record profitability from its capitation and value-based care segments. Enhanced operational efficiencies and a robust pipeline of new providers and visit volumes are expected to sustain the firm's positive momentum into future fiscal periods.

Bears say

Privia Health Group Inc faces significant challenges due to anticipated declines in Medicaid enrollment, specifically an expected 8%-10% decrease in membership stemming from re-determination activities post-public health emergency. The company's guidance indicates a sequential decline in EBITDA, following a strong Q3, suggesting potential weakness in profitability. Additionally, the expectation for a 2% quarter-over-quarter decline in a period generally characterized by seasonal growth further underscores the company's vulnerable position in the current market environment.

PRVA has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 69% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Privia Health Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Privia Health Group (PRVA) Forecast

Analysts have given PRVA a Buy based on their latest research and market trends.

According to 13 analysts, PRVA has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Privia Health Group (PRVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.